Cargando…

ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis

Alternative splicing is a common physiologic mechanism to generate numerous distinct gene products from one gene locus, which can result in unique gene products with differing important functional outcomes depending on cell context. Aberrant alternative splicing is a hallmark of cancer that can cont...

Descripción completa

Detalles Bibliográficos
Autores principales: Rieger, Ingmar, Tsintari, Vasileia, Overkamp, Mathis, Fend, Falko, Lopez, Charles D., Schittenhelm, Marcus M., Kampa-Schittenhelm, Kerstin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602356/
https://www.ncbi.nlm.nih.gov/pubmed/34805267
http://dx.doi.org/10.3389/fmolb.2021.727203
_version_ 1784601561780977664
author Rieger, Ingmar
Tsintari, Vasileia
Overkamp, Mathis
Fend, Falko
Lopez, Charles D.
Schittenhelm, Marcus M.
Kampa-Schittenhelm, Kerstin M.
author_facet Rieger, Ingmar
Tsintari, Vasileia
Overkamp, Mathis
Fend, Falko
Lopez, Charles D.
Schittenhelm, Marcus M.
Kampa-Schittenhelm, Kerstin M.
author_sort Rieger, Ingmar
collection PubMed
description Alternative splicing is a common physiologic mechanism to generate numerous distinct gene products from one gene locus, which can result in unique gene products with differing important functional outcomes depending on cell context. Aberrant alternative splicing is a hallmark of cancer that can contribute to oncogenesis and aggressiveness of the disease as well as resistance to therapy. However, aberrant splicing might also result in novel targets for cancer therapy. ASPP2 is a haplo-insufficient tumor suppressor, that functions through both p53-dependent as well as p53-independent mechanisms to enhance cell death after stress. Interestingly, the common human tumor TP53 mutations result in a loss of the binding sites to ASPP2, leading to impaired induction of apoptosis. Vice versa, attenuation of ASPP2 has been described to be associated with high-risk disease, therapy failure and poor clinical outcome especially in tumors harboring the TP53 wildtype (WT) isoform. We have recently identified a novel, dominant-negative splicing variant of ASPP2, named ASPP2κ, with oncogenic potential. Exon-skipping results in a reading-frame shift with a premature translation stop, omitting most of the ASPP2 C-terminus - which harbors the p53-binding domain. Consequently, the ASPP2-p53 interaction is abrogated, which in part impacts on oncogenesis, aggressiveness of disease and response to therapy. Since ASPP2κ has been shown in hematologic malignancies to promote tumorigenesis, we further wished to determine if aberrant ASPP2κ expression plays a role in human solid tumors. In this report, we find that ASPP2κ is frequently expressed in human colorectal tumors (CRC). Using ASPP2κ overexpressing and interference CRC models, we demonstrate a functional role of ASPP2κ in contributing to oncogenesis and resistance to therapy in CRC by 1) enhancing proliferation, 2) promoting cell migration and, 3) conferring resistance to chemotherapy induced apoptosis. Our findings have far-reaching consequences for future diagnostic and therapeutic strategies for ASPP2κ expressing colorectal cancer patients and provide proof-of-principle to further explore ASPP2κ as potential predictive marker and target for therapy in clinical trials.
format Online
Article
Text
id pubmed-8602356
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86023562021-11-20 ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis Rieger, Ingmar Tsintari, Vasileia Overkamp, Mathis Fend, Falko Lopez, Charles D. Schittenhelm, Marcus M. Kampa-Schittenhelm, Kerstin M. Front Mol Biosci Molecular Biosciences Alternative splicing is a common physiologic mechanism to generate numerous distinct gene products from one gene locus, which can result in unique gene products with differing important functional outcomes depending on cell context. Aberrant alternative splicing is a hallmark of cancer that can contribute to oncogenesis and aggressiveness of the disease as well as resistance to therapy. However, aberrant splicing might also result in novel targets for cancer therapy. ASPP2 is a haplo-insufficient tumor suppressor, that functions through both p53-dependent as well as p53-independent mechanisms to enhance cell death after stress. Interestingly, the common human tumor TP53 mutations result in a loss of the binding sites to ASPP2, leading to impaired induction of apoptosis. Vice versa, attenuation of ASPP2 has been described to be associated with high-risk disease, therapy failure and poor clinical outcome especially in tumors harboring the TP53 wildtype (WT) isoform. We have recently identified a novel, dominant-negative splicing variant of ASPP2, named ASPP2κ, with oncogenic potential. Exon-skipping results in a reading-frame shift with a premature translation stop, omitting most of the ASPP2 C-terminus - which harbors the p53-binding domain. Consequently, the ASPP2-p53 interaction is abrogated, which in part impacts on oncogenesis, aggressiveness of disease and response to therapy. Since ASPP2κ has been shown in hematologic malignancies to promote tumorigenesis, we further wished to determine if aberrant ASPP2κ expression plays a role in human solid tumors. In this report, we find that ASPP2κ is frequently expressed in human colorectal tumors (CRC). Using ASPP2κ overexpressing and interference CRC models, we demonstrate a functional role of ASPP2κ in contributing to oncogenesis and resistance to therapy in CRC by 1) enhancing proliferation, 2) promoting cell migration and, 3) conferring resistance to chemotherapy induced apoptosis. Our findings have far-reaching consequences for future diagnostic and therapeutic strategies for ASPP2κ expressing colorectal cancer patients and provide proof-of-principle to further explore ASPP2κ as potential predictive marker and target for therapy in clinical trials. Frontiers Media S.A. 2021-11-05 /pmc/articles/PMC8602356/ /pubmed/34805267 http://dx.doi.org/10.3389/fmolb.2021.727203 Text en Copyright © 2021 Rieger, Tsintari, Overkamp, Fend, Lopez, Schittenhelm and Kampa-Schittenhelm. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Rieger, Ingmar
Tsintari, Vasileia
Overkamp, Mathis
Fend, Falko
Lopez, Charles D.
Schittenhelm, Marcus M.
Kampa-Schittenhelm, Kerstin M.
ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
title ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
title_full ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
title_fullStr ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
title_full_unstemmed ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
title_short ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
title_sort aspp2κ is expressed in human colorectal carcinoma and promotes chemotherapy resistance and tumorigenesis
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602356/
https://www.ncbi.nlm.nih.gov/pubmed/34805267
http://dx.doi.org/10.3389/fmolb.2021.727203
work_keys_str_mv AT riegeringmar aspp2kisexpressedinhumancolorectalcarcinomaandpromoteschemotherapyresistanceandtumorigenesis
AT tsintarivasileia aspp2kisexpressedinhumancolorectalcarcinomaandpromoteschemotherapyresistanceandtumorigenesis
AT overkampmathis aspp2kisexpressedinhumancolorectalcarcinomaandpromoteschemotherapyresistanceandtumorigenesis
AT fendfalko aspp2kisexpressedinhumancolorectalcarcinomaandpromoteschemotherapyresistanceandtumorigenesis
AT lopezcharlesd aspp2kisexpressedinhumancolorectalcarcinomaandpromoteschemotherapyresistanceandtumorigenesis
AT schittenhelmmarcusm aspp2kisexpressedinhumancolorectalcarcinomaandpromoteschemotherapyresistanceandtumorigenesis
AT kampaschittenhelmkerstinm aspp2kisexpressedinhumancolorectalcarcinomaandpromoteschemotherapyresistanceandtumorigenesis